Literature DB >> 7527304

Biologic agents as biochemical modulators: pharmacologic basis for the interaction of cytotoxic chemotherapeutic drugs and interferon.

S Wadler1, E L Schwartz.   

Abstract

Biochemical modulation of cytotoxic cancer chemotherapeutic agents is one means of enhancing the activity and selectivity of antitumor drugs. Traditionally this approach has utilized detailed information regarding a particular enzymatic reaction or biochemical pathway to develop potential modulating agents. In contrast, the reported clinical therapeutic activity of IFN in combination with cytotoxic agents has prompted a reexamination of the biochemical actions of the cytokine. Interferon elicits a number of cellular actions that might contribute to its pharmacologic activity, including both direct antitumor effects and host-mediated actions. The best understood are those related to the cytotoxicity of the fluoropyrimidine antimetabolites and include enzymatic reactions involved in fluoropyrimidine metabolic activation, catabolism, and interaction with its target enzyme. However, even in this instance, a mechanistic association of a specific pharmacologic action with therapeutic activity remains to be determined. These studies demonstrate that cytokines and other biologic agents may exert specific biochemical modulations that augment (or potentially attenuate) the activity of the cytotoxic chemotherapeutic agents.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7527304     DOI: 10.1007/BF00686280

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  87 in total

1.  Malignant transformation by a mutant of the IFN-inducible dsRNA-dependent protein kinase.

Authors:  A E Koromilas; S Roy; G N Barber; M G Katze; N Sonenberg
Journal:  Science       Date:  1992-09-18       Impact factor: 47.728

2.  Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a.

Authors:  C W White; H M Sondheimer; E C Crouch; H Wilson; L L Fan
Journal:  N Engl J Med       Date:  1989-05-04       Impact factor: 91.245

3.  Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte.

Authors:  P Solal-Celigny; E Lepage; N Brousse; F Reyes; C Haioun; M Leporrier; M Peuchmaur; A Bosly; Y Parlier; P Brice
Journal:  N Engl J Med       Date:  1993-11-25       Impact factor: 91.245

4.  Lack of correlation between thymidine kinase activity and the antiviral or antiproliferative response to interferon.

Authors:  M Divizia; C Baglioni
Journal:  Virology       Date:  1984-02       Impact factor: 3.616

5.  Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma. Assessment of activity and toxicity.

Authors:  N Kemeny; A Younes; K Seiter; D Kelsen; P Sammarco; L Adams; S Derby; P Murray; C Houston
Journal:  Cancer       Date:  1990-12-15       Impact factor: 6.860

6.  Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta.

Authors:  E C Borden; Y A Sidky; J F Hatcher; G T Bryan
Journal:  Cancer Res       Date:  1988-05-01       Impact factor: 12.701

Review 7.  Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review.

Authors:  S Wadler; E L Schwartz
Journal:  Cancer Res       Date:  1990-06-15       Impact factor: 12.701

8.  Treatment of carcinoma of the esophagus with 5-fluorouracil and recombinant alfa-2a-interferon.

Authors:  S Wadler; S Fell; H Haynes; H J Katz; A Rozenblit; R Kaleya; P H Wiernik
Journal:  Cancer       Date:  1993-03-01       Impact factor: 6.860

9.  Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2.

Authors:  H Harada; M Kitagawa; N Tanaka; H Yamamoto; K Harada; M Ishihara; T Taniguchi
Journal:  Science       Date:  1993-02-12       Impact factor: 47.728

10.  Interaction between 5-fluorouracil, [6RS]leucovorin, and recombinant human interferon-alpha 2a in cultured colon adenocarcinoma cells.

Authors:  J A Houghton; D A Adkins; A Rahman; P J Houghton
Journal:  Cancer Commun       Date:  1991-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.